First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer. Shaw AT, Bauer TM, de Marinis F, Felip E, et al. N Engl J Med 2020;383:2018-2029.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Shaw AT, Bauer TM, de Marinis F, Felip E, et al. First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer. N Engl J Med 2020;383:2018-2029.
PMID: 33207094